Multivariate analysis of risk factors in stage 4 neuroblastoma patients over the age of one year treated with megatherapy and stem-cell transplantation: A report from the European Bone Marrow Transplantation Solid Tumor Registry

Journal of Clinical Oncology

Volumn 16, Issue 3, 1998, Pages 953-965

  Ladenstein, Ruth ^a   Philip, T ^a   Lasset, C ^a   Hartmann, O ^a   Garaventa, A ^a   Pinkerton, R ^a   Michon, J ^a   Pritchard, J ^a   Klingebiel, T ^a   Kremens, B ^a   Pearson, A ^a   Coze, C ^a   Paolucci, P ^a   Frappaz, D ^a   Gadner, H ^a   Chauvin, F ^a  

^a CENTRE LÉON BÉRARD   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ALKYLATING AGENT; ANTHRACYCLINE ANTIBIOTIC AGENT; CYCLOPHOSPHAMIDE; DACARBAZINE; DOXORUBICIN; ETOPOSIDE; IFOSFAMIDE; PEPTICHEMIO; TENIPOSIDE; VINCRISTINE;

ARTICLE; BONE MARROW TRANSPLANTATION; CANCER REGRESSION; CANCER SURVIVAL; CHILD; CHILDHOOD CANCER; CLINICAL PROTOCOL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG MEGADOSE; HUMAN; MAJOR CLINICAL STUDY; MULTICENTER STUDY; NEUROBLASTOMA; PRIORITY JOURNAL; PROGNOSIS; REGISTER; STEM CELL TRANSPLANTATION; TREATMENT OUTCOME;

EID: 0031911489     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.1998.16.3.953     Document Type: Article

References (66)

1. Hartmann O, Scopinario M, Tournade MF, et al: Neuroblastomes traités à l'Institut Gustave Roussy de 1975 à 1979, cent soixant-treize cas. Arch Fr Pediatr 40:15-21, 1983
2. Philip T, Zucker JM, Bernard JL, et al: Improved survival at 2 and 5 years in the LMCE1 unselected group of 72 children with stage IV neuroblastoma older than 1 year of age at diagnosis: Is cure possible in a small subgroup? J Clin Oncol 9:1037-1044, 1991
3. Hartmann O, Kalifa C, Beaujean F, et al: Treatment of advanced neuroblastoma with high-dose melphalan and autologous bone marrow transplantation. Cancer Chemother Pharmacol 16:165-169, 1986
4. Hartmann O, Benhamou E, Beaujean F, et al: Repeated high-dose chemotherapy followed by purged autologous bone marrow transplantation as consolidation therapy in metastatic neuroblastoma. J Clin Oncol 5:1205-1211, 1987
5. Berthold F, Bender-Götze CH, Dopfer R, et al: Myeloablative chemo- and radiotherapy with autologous and allogenic bone marrow reconstitution in children with metastatic neuroblastoma. Klin Pädiatr 200:221-225, 1988
6. Corbett R, Pinkerton R, Pritchard J, et al: Pilot study of high-dose vincristine, etoposide, carboplatin and melphalan with autologous bone marrow rescue in advanced neuroblastoma. Eur J Cancer 28A:1324-1328, 1992
7. Gordon SJ, Pearson AD, Reid M, et al: Toxicity of single day high-dose vincristine, melphalan, etoposide and carboplatin. Consolidation with autologous bone marrow rescue in advanced neuroblastoma. Eur J Cancer 28A:1319-1323, 1992
8. Kletzel M, Becton DL, Berry DH: Single institution experience with high-dose cyclophosphamide, continuous infusion vincristine, escalating doses of VP-16-213, and total body irradiation with unpurged bone marrow rescue in children with neuroblastoma. Med Pediatr Oncol 20:64-67, 1992
9. Kushner BH, O'Reiily RJ, Mandell LR, et al: Myeloablative combination chemotherapy without total body irradiation for neuroblastoma. J Clin Oncol 9:274-279, 1991
10. Dini G, Lamino E, Garaventa A, et al: Myeloablative therapy and unpurged autologous bone marrow transplantation for poor prognosis neuroblastoma: Report of 34 cases. J Clin Oncol 9:962-969, 1991
11. Graham-Pole J, Casper J, Elfenbein G, et al: High-dose chemoradiotherapy supported by marrow infusions for advanced neuroblastoma: A Pediatric Oncology Group Study. J Clin Oncol 9:152-158, 1991
12. Zucker JM, Philip T, Bernard JL, et al: Single or double consolidation treatment according to remission status after initial therapy in metastatic neuroblastoma: First results of the LMCE 3 study in 40 patients. Prog Clin Biol Res 366:543-551, 1991
13. Matthay KK, O'Leary MC, Ramsay NK, et al: Role of myeloablative therapy in improved outcome for high risk neuroblastoma: Review of recent Children's Cancer Group results. Eur J Cancer 31A:572-575, 1995
14. Kamani N, August CS, Bunin N, et al: A study of thiotepa, etoposide and fractionated total body irradiation as a preparative regimen prior to bone marrow transplantation for poor prognosis patients with neuroblastoma. Bone Marrow Transplant 17:911-916, 1996
15. Garaventa A, Rondelli R, Lanino E, et al: Myeloablative therapy and bone marrow rescue in advanced neuroblastoma. Report from the Italian Bone Marrow Transplant Registry. Italian Association of Pediatric Hematology-Oncology, BMT Group. Bone Marrow Transplant 18:125-130, 1996
16. Stram DO, Matthay KK, O'Leary M, et al: Consolidation chemoradiotherapy and autologous bone marrow transplantation versus continued chemotherapy for metastatic neuroblastoma: A report of two concurrent Children's Cancer Group studies. J Clin Oncol 14:2417-2426, 1996
17. McCowage GB, Vowels MR, Shaw PJ, et al: Autologous bone marrow transplantation for advanced neuroblastoma using teniposide, doxorubicine, melphalan, cisplatin, and total-body irradiation. J Clin Oncol 13:2789-2795, 1995
18. Ladenstein R, Lasset C, Hartmann O, et al: Impact of megatherapy on survival after relapse from stage IV neuroblastoma in patients over I year of age at diagnosis: A report from the European Group for Bone Marrow Transplantation. J Clin Oncol 11:2330-2341, 1993
19. Cervera A, Kingston JE, Malpas JS: Late recurrences of neuroblastoma: A report of five cases and review of the literature. Pediatr Hematol Oncol 7:311-322, 1990
20. Caron H, van Sluis P, de Kraker J: Allelic loss of chromosome 1p as a predictor of unfavorable outcome in patients with neuroblastoma. N Engl J Med 334:225-230, 1996
21. Rubie H, Plantaz D, Michon J, et al: Localized neuroblastoma: N-myc gene amplification is the main prognostic factor and postoperative treatment can be deleted in infants. SIOP. Med Pediatr Oncol 21:582, 1993 (abstr 110)
22. Seeger RC, Brodeur GM, Sather R, et al: Association of multiple copies of the N-myc oncogene with rapid progression of neuroblastomas. N Engl J Med: 313:1111-1116, 1985
23. Brodeur GM, Azar C, Brother M, et al: Neuroblastoma: Effect of genetics on prognosis and treatment. Cancer 70:1685-1694, 1992
24. Look AT, Hayes FA, Shuster JJ, et al: Clinical relevance of tumor cell ploidy and n-myc gene amplification in childhood neuroblastoma: A Pediatric Oncology Group Study. J Clin Oncol 9:581-591, 1991
25. Ambros PF, Ambros IM, Ladenstein R, et al: Neuroblastoma: Impact of biological characteristics on treatment strategies. Onkologie 18:548-555, 1995
26. Ladenstein R, Lasset C, Philip T: Treatment duration before bone marrow transplantation in stage IV neuroblastoma. Lancet 340:916, 1992 (letter)
27. Gross N, Beretta C, Peruisseau G, et al: CD44H expression by human neuroblastoma cells: Relation to n-myc amplification and lineage differentiation. Cancer Res 54:4238-4242, 1994
28. Combaret V, Gross N, Lasset C, et al: Clinical relevance of CD44 cell-surface expression and n-myc gene amplification in a multicentric analysis of 121 pediatric neuroblastomas. J Clin Oncol 14:25-34, 1996
29. Evans AE, D'Angio GJ, Propert K, et al: Prognostic factors in neuroblastoma. Cancer 59:1853-1859, 1987
30. Berthold F, Trechow R, Utsch S, et al. Prognostic factors in metastatic neuroblastoma. Am J Pediatr Haematol Oncol 14:207-215, 1992
31. Ladenstein R, Favrot M, Lasset C, et al: Indication and limits of megatherapy and bone marrow transplantation in high risk neuroblastoma. A single center analysis of prognostic factors. Eur J Cancer 29A:947-956, 1993
32. Shafford EA, Rogers DW, Pritchard J: Advanced neuroblastoma: Improved response rate using a multidrug regimen (OPEC) including sequential cisplatinum and VM26. J Clin Oncol 2:742-747, 1984
33. Rosen EM, Cassady JR, Frantz CN, et al. Neuroblastoma: The Joint Center for Radiation Therapy/Dana-Farber Cancer Institute/ Children's Hospital Experience. J Clin Oncol 2:719-732, 1984
34. Ladenstein R, Urban C, Gadner H, et al: First experience with prognostic factors in unselected neuroblastoma patients. The Austrian Neuroblastoma 87 Study. Eur J Cancer 31A:637-641, 1995
35. Bernard JL, Philip T, Zucker JM, et al: Sequential cisplatinum/ VM26 and vincristine-cyclophosphamide-doxorubicin in metastatic neuroblastoma. An effective alternation non-cross resistant regimen? J Clin Oncol 5:1912-1959, 1987
36. Hartmann O, Pinkerton CR, Philip T, et al: Very high dose cisplatin and etoposide in children with untreated advanced neuroblastoma. J Clin Oncol 6:44-50, 1988
37. Philip T, Ghalie R, Pinkerton R, et al: A phase II study of high-dose cisplatin and VP16 in neuroblastoma: A report from the Société Francaise d'Oncologie Pédiatrique. J Clin Oncol 1:941-950, 1987
38. 2). A report from the LMCE group; in Evans AE, D'Angio GJ, Seeger RC (eds): Advances in Neuroblastoma Research 2. New York, NY, Liss, 1988, pp 573-582
39. Frappaz D, Michon J, Hartmann O, et al: VP16/ carboplatin in neuroblastoma: A SFOP phase II study. J Clin Oncol 10:1-9, 1992
40. Pinkerton CR, Zucker JM, Hartmann O, et al: Short duration, high-dose, alternating chemotherapy in metastatic neuroblastoma. (ENSG 3C regimen). Br J Cancer 62:319-323, 1990
41. Pearson AD, Craft AW, Pinkerton CR, et al: High-dose rapid schedule chemotherapy for disseminated neuroblastoma. Eur J Cancer 28A: 1654-1659, 1992
42. Kellie SJ, de Kraker J, Lilleyman-Bowman A, et al: Ifosfamide in previously untreated disseminated neuroblastoma. Eur J Cancer Clin Oncol. 24:903-908, 1988
43. Berthold F, Burdach S, Kremens B, et al: The role of chemotherapy in the treatment of children with neuroblastoma stage IV: The GPO (German Paediatric Oncology Society) experience. Klin Paediatr 202: 262-269, 1990
44. Castello MA, Clerico A, Jenker A, et al: A pilot study of high dose carboplatin and pulsed etoposide in the treatment of childhood solid tumors. Pediatr Hematol Oncol 7:129-135, 1990
45. Garaventa A, Guerra P, Arrighini A, et al: Treatment of advanced neuroblastoma with J-131 meta-Iodobenzylguanidine. Cancer 67:922-928, 1991
46. Donfrancesco A, Deb G, Dominici C, et al: Deferoxamine, cyclophosphamide, etoposide, carboplatin and thiotepa (D-CECaT): A new cytoreductive chelation-chemotherapy regimen in patients with advanced neuroblastoma. Am J Clin Oncol 15:319-322, 1992
47. Kushner BH, Helson L: Coordinated use of sequentially escalated cyclophosphamide and cell-specific chemotherapy (N4SE protocol) for advanced neuroblastoma: Experience with 100 patients. J Clin Oncol 5:1746-1750, 1987
48. Castel V, Garcia MP, Melero C, et al: The treatment of advanced neuroblastoma: Results of the Spanish Neuroblastoma Study Group (SNSG) studies. Eur J Cancer. 31 A:642-645, 1995
49. Pritchard J, McElwain TJ, Graham-Pole J, et al: High dose melphalan with autologous bone marrow for the treatment of advanced neuroblastoma. Br J Cancer 45:86-94, 1982
50. Emminger W, Emminger-Schmidmeier W, Peters C, et al: Is treatment intensification by adding etoposide and carboplatin to fractionated total body irradiation and melphalan acceptable in children with solid tumors with respect to toxicity? Bone Marrow Transplant 8:119-123, 1991
51. Philip T, Ladenstein R, Zucker JM, et al: Double megatherapy and autologous bone marrow transplantation for advanced neuroblastoma: The LMCE2 study. Br J Cancer 67:119-127, 1993
52. Kemshead JT, Heath L, Gibson FM, et al: Magnetic microspheres and monoclonal antibodies for the depletion of neuroblastoma cells from bone marrow: Experiences, improvements and observations. Br J Cancer 54:771-778, 1986
53. Kaizer H, Stuart RK, Brookmeyer R, et al: Autologous bone marrow transplantation in acute leukemia: A phase I study of in vitro treatment of marrow with 4-hydroperoxycyclophospamide to purge tumor cells. Blood 65:504-507, 1985
54. Kaplan E, Meier P: Nonparametric estimation from incomplete observations. J Am Stat Assoc 53:457-481, 1958
55. Cox R: Regression models and life tables. J R Stat Soc 34:187-202, 1972
56. BMDP Statistical Software Inc: Los Angeles, CA, University of California, 1983
57. Anderson JR, Coccia PF: Is more better? Dose intensity in neuroblastoma. J Clin Oncol 9:902-904, 1991 (editorial)
58. Shuster JJ, Cantor AB, MC Williams N, et al: The prognostic significance of autologous bone marrow transplantation in advanced neuroblastoma. J Clin Oncol 9:1045-1049, 1991
59. 99Tc MDP scintigraphy. J Nucl Biol Med 37:107-114, 1993
60. Lastoria S, Maurea S, Caraco C, et al: Iodine 131 metaiodobenzylguanidine scintigraphy for localization of lesions in children with neuroblastoma: Comparison with computed tomography and ultrasonography. Eur J Nucl Med 20:1161-1167, 1993
61. Brodeur G, Seeger RC, Barret A, et al: International criteria for diagnosis, staging, and response to treatment in patients with neuroblastoma. J Clin Oncol 6:1874-1881, 1988
62. Cheung NK, Heller G: Chemotherapy dose intensity correlates strongly with response, median survival and median progression-free survival in metastatic neuroblastoma. J Clin Oncol 19:1050-1058, 1991
63. Carlsen NLT, Schroeder H, Bro PV, et al: Response to multimodal treatment in advanced neuroblastomas. Factors associated with complete remission induction, and factors associated with prolonged survival. Anticancer Res 9:836-844, 1989
64. Sansone R, Di Martino D, Lanino E, et al: n-Myc amplification does not effect survival of neuroblastoma patients treated with autologous bone marrow transplantation. Bone Marrow Transplant 7:133-135, 1991
65. Giorgiani G, Bozzola M, Locatelli F, et al: Role of busulfan and total body irradiation on growth of prepubertal children receiving bone marrow transplantation and results of treatment with recombinant human growth hormone. Blood 15 86:825-831, 1995
66. Smedler AC, Bolme P: Neuropsychological deficits in very young bone marrow transplant recipients. Acta Paediatr 4:429-433, 1995